Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...303304305306307308309310311312313...401402»
  • ||||||||||  Clinical, Journal:  Lower-limb muscle strength: normative data from an observational population-based study. (Pubmed Central) -  Dec 18, 2020   
    Limited eligible reviews restricted synthesis and interpretation of findings. These data will be useful for quantifying the extent of dynapenia and poor muscle quality among adults in the general population in the face of frailty, sarcopenia and other age-related muscle dysfunction.
  • ||||||||||  Clinical, Journal:  Clinical Features of Sarcopenia in Patients with Lumbar Spinal Stenosis. (Pubmed Central) -  Dec 18, 2020   
    These data will be useful for quantifying the extent of dynapenia and poor muscle quality among adults in the general population in the face of frailty, sarcopenia and other age-related muscle dysfunction. Patients with LSS and sarcopenia have a higher degree of slippage and lower BMI, BMD, and physical function, and reported more severe low back pain, compared with those without sarcopenia.
  • ||||||||||  Clinical, Review, Journal:  Innovations in Geroscience to enhance mobility in older adults. (Pubmed Central) -  Dec 18, 2020   
    Thus, the purpose of the present review is to describe evolving interventional approaches to enhance mobility and maintain healthspan in the growing population of older adults in the United States and countries throughout the world. Such interventions are likely to be greatly assisted by technological advances and the widespread adoption of virtual communications during and after the COVID-19 era.
  • ||||||||||  Journal:  Neuromuscular Disorders in the Oldest-Old (Pubmed Central) -  Dec 17, 2020   
    Providing appropriate medical care for patients with neuromuscular disorders will extend healthy life expectancy. In this review, previous studies on age-related changes in the neuromuscular system were summarized and the common neuromuscular disorders in the oldest-old were reviewed.
  • ||||||||||  Review, Journal:  Comprehensive Model for Physical and Cognitive Frailty: Current Organization and Unmet Needs. (Pubmed Central) -  Dec 17, 2020   
    Thus, the purpose of this manuscript is to provide an excursus on current clinical practice, enforced by aneddoctical cases. The analysis of the current state of the art seems to support the urgent need of comprehensive organizational model incorporating physical and cognitive spheres in the same umbrella.
  • ||||||||||  Review, Journal:  Malnutrition in cirrhosis: More food for thought. (Pubmed Central) -  Dec 17, 2020   
    We also discuss management strategies to optimise nutritional status in this patient group, which target the inter-related mechanisms unique to advanced liver disease. Finally, future research requirements are suggested, to develop effective treatments for one of the most common and debilitating complications afflicting cirrhotic patients.
  • ||||||||||  Review, Journal:  ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19. (Pubmed Central) -  Dec 17, 2020   
    Thus, the potential association of sarcopenia with ACE2 and the associated molecules outside of RAS is also presented herein. Further, we introduce the transcriptional regulation of muscle ACE2 by drugs or exercise, and briefly discuss the potential role of ACE2 in the development of COVID-19.
  • ||||||||||  Review, Journal:  Hypovitaminosis D and Aging: Is There a Role in Muscle and Brain Health? (Pubmed Central) -  Dec 17, 2020   
    Hypovitaminosis D is common amongst old patients and has been proposed as causative of several chronic diseases. Here we review the role of hypovitaminosis D and vitamin D supplementation in sarcopenia and dementia, from bench to bedside.
  • ||||||||||  Trial completion date, Trial primary completion date:  Muscle Assessment Through Ultrasound in the Evaluation of Acute Sarcopenia (clinicaltrials.gov) -  Dec 17, 2020   
    P=N/A,  N=200, Recruiting, 
    Here we review the role of hypovitaminosis D and vitamin D supplementation in sarcopenia and dementia, from bench to bedside. Trial completion date: Nov 2020 --> Apr 2021 | Trial primary completion date: Oct 2020 --> Mar 2021
  • ||||||||||  Kremezin (AST-120) / Mitsubishi Tanabe
    Trial completion, Trial completion date, Trial primary completion date:  RECOVERY: Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease (clinicaltrials.gov) -  Dec 17, 2020   
    P4,  N=150, Completed, 
    Trial completion date: Nov 2020 --> Apr 2021 | Trial primary completion date: Oct 2020 --> Mar 2021 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020
  • ||||||||||  Journal:  Moderate hypoxia promotes skeletal muscle cell growth and hypertrophy in C2C12 cells. (Pubmed Central) -  Dec 17, 2020   
    Compared with normoxia, a 10% oxygen environment promoted myogenin and the expression of mTOR, p70s6K, and the metabolic signal AMPK. We concluded that a hypoxic environment, if not too severe, may promote muscle differentiation and hypertrophy by increasing the expression of proteins associated with muscle cell differentiation and hypertrophy.
  • ||||||||||  Review, Journal:  Reference Values for Skeletal Muscle Mass - Current Concepts and Methodological Considerations. (Pubmed Central) -  Dec 17, 2020   
    In conclusion, results for SM can only be compared with reference values using the same method, BIA- or DXA-device and an appropriate reference population. Limitations of proxies for total SM as well as normalization of SM for FM are important content-related issues that need to be considered in longitudinal studies, populations with obesity or older subjects.
  • ||||||||||  Clinical, Journal:  Determinants of Adherence in Time-Restricted Feeding in Older Adults: Lessons from a Pilot Study. (Pubmed Central) -  Dec 17, 2020   
    Six participants, however, did not fully understand the requirements of the fasting regimen, despite being provided with specific instructions and a pictorial guide at a baseline visit. This suggests that more instruction and/or participant contact is needed in the early stages of a TRF intervention to promote adherence.
  • ||||||||||  Clinical, Journal:  Prognostic value of sarcopenia in patients with colorectal liver metastases undergoing hepatic resection. (Pubmed Central) -  Dec 17, 2020   
    Multinodularity (>3) (HR 1.750; 95% CI, 1.066-2.872; p = 0.027), high aspartate aminotransferase level (HR 1.024; 95% CI, 1.003-1.046; p = 0.025) and male gender (HR 1.688; 95% CI, 1.036-2.748; p = 0.035) were independent factors of RFS. In conclusion, despite no significance in whole cohort, sarcopenia was predictive of worse OS in patients with multiple CRLM after partial hepatectomy.
  • ||||||||||  Review, Journal:  Role of damage and management in muscle hypertrophy: Different behaviors of muscle stem cells in regeneration and hypertrophy. (Pubmed Central) -  Dec 16, 2020   
    When considering MuSC-based therapy for atrophy, including sarcopenia, it will be indispensable to elucidate MuSC behaviors in muscles that exhibit non-degenerative damage, because degenerated myofibers are not present in the atrophied muscles. In this review, we summarize recent findings concerning the relationship between MuSCs and hypertrophy, and discuss what remains to be discovered to inform the development and application of relevant treatments for muscle atrophy.
  • ||||||||||  Clinical, Journal:  The value of L3 skeletal muscle index in evaluating preoperative nutritional risk and long-term prognosis in colorectal cancer patients. (Pubmed Central) -  Dec 16, 2020   
    Multivariate Cox regression analysis revealed preoperative low L3SMI adversely affected disease-free survival (p < 0.001, HR 1.894 (95% CI: 1.330-2.698)), and overall survival (p < 0.001, HR 2.030 (95% CI: 1.420-2.902)). In conclusion, L3SMI is a useful supplement for screening preoperative nutritional risk and diagnosing sarcopenia, and a potential clinical indicator that can be used to predict the prognosis of CRC patients, especially TNM stage II patients.
  • ||||||||||  Review, Journal:  Dehydroepiandrosterone and age-related musculoskeletal diseases: connections and therapeutic implications. (Pubmed Central) -  Dec 16, 2020   
    Extensive detailed descriptions of the pathogenesis of each of these musculoskeletal disorders are beyond the scope of this review; instead, we aim to highlight the association of changes in DHEA with the processes of OP, sarcopenia and OA. A special focus will also be placed on the overlapping pathogeneses among these three diseases, and the molecular mechanisms underlying the action of DHEA against these diseases are discussed or postulated.